Revenue

P3 Health Partners stuns Wall Street with a swing to profitability, but a deeper dive reveals one-time gains and a strategic pivot. Is this the new playbook?

Entravision's ad-tech unit soared 230% on AI, driving record profit. But with its legacy media arm in decline, can this tech pivot redefine its future?

Facing a 50% revenue collapse and mounting losses, The Arena Group is rebranding to Paradium.AI, a high-stakes pivot to save itself with technology.

In a blockbuster deal with Boeing, Archer acquires key assets to build a 'physical AI' powerhouse. But with soaring losses, is it a masterstroke or a costly bet?

Fluent's Q2 results reveal a dramatic pivot, with Commerce Media Solutions booming 90%. But can this growth and a new in-store bet outrun a stark 'going concern' warning?

Sumisho Air Lease reports a 98% profit drop in its first post-acquisition quarter, but accounting shifts mask a deeper strategic realignment for the lessor.

BODi posts a fourth straight profitable quarter, but with revenue and subscribers in freefall, is its dramatic cost-cutting a sign of health or stagnation?

Insight Molecular Diagnostics has key regulatory and reimbursement wins for its game-changing transplant test, but a high cash burn creates a high-stakes race to commercialization.

Tactile Medical's impressive Q2 profit growth is tempered by a product launch stumble, testing its execution as it places big bets on new markets and tech.

Amidst declining revenue and layoffs, Rapid7's new CEO is making a bold bet on a focused, AI-driven strategy. Is this the path to renewed strength?

Beyond the hype of AI models and drones, Kopin is building the critical optical networks and displays that make them possible. A look at its strategic Q2.

Strong Attruby sales and new data showing superiority fuel BridgeBio’s momentum as it prepares for three FDA decisions, backed by a new $1B financing.

Wah Fu Education's stock soared after announcing a radical pivot to enterprise AI. But can custom models for agriculture and medicine save a struggling company?

Healthcare Management Administrators appoints Diane Zalewski as CEO. Her Evernorth success signals a focus on innovation amid rising costs for self-funded employers.

Indian pharma giant Lupin secures FDA approval for a generic heart drug, challenging AstraZeneca and signaling a new era of cost competition in specialty medicine.

Beyond the record revenue, Applied BioCode's growth reveals a strategy of solving lab bottlenecks and securing reimbursement, positioning it against industry giants.

With a fresh $16.2M, Chaince Digital is betting big on building regulated infrastructure for tokenization before institutional demand fully arrives.

Freedom Holding Corp. posts a 40% revenue jump but a drop in net income, signaling an aggressive, high-cost strategy centered on its SuperApp and major acquisitions.

AGCO's stock plunged after a surprise guidance cut, triggering a legal probe. We dissect if this was just a market downturn or a failure in transparency.

A shocking $90M guidance cut and a securities probe at Myriad Genetics reveal more than a bad quarter; they expose deep cracks in the genetic testing market.